American Cell Therapies Company Selects ValGenesis VLMS to Digitize Multiple Validation Lifecycle Processes News provided by Share this article Share this article SAN FRANCISCO, Jan. 25, 2021 /PRNewswire/ -- ValGenesis Inc., a market leader in Enterprise Validation Lifecycle Management Solutions (VLMS), today announced that a U.S. based cell therapies company has selected ValGenesis VLMS – the industry's most trusted electronic validation lifecycle management system – to digitize multiple corporate validation lifecycle processes across the organization. The company develops novel allogeneic living drugs for oncology that overcome the limitations of first-generation cell therapies. As a fast-growing organization with limited resources, the company is looking to the user-friendly ValGenesis VLMS to help them plan, define, and manage all validation operations, ensuring that the right amount of validation is applied to every system and asset being validated. ValGenesis VLMS will be used to define and set global validation standards and best practices across the organization, while streamlining validation processes to adhere to the most rigorous data integrity and regulatory standards. Additionally, ValGenesis' s proven 100% paperless approach to all validation types will enable the company to sustain a completely digital approach to validation execution. The ability to efficiently manage validation operations through real-time collaboration, transparency, and traceability, will enable the company to sustain momentum towards regulatory approvals and manufacturing. The ValGenesis system is scheduled to go live in the second quarter of 2021.